Q2 2017 EPS Estimates for Henry Schein, Inc. Raised by Northcoast Research (HSIC)
Henry Schein, Inc. (NASDAQ:HSIC) – Equities researchers at Northcoast Research raised their Q2 2017 earnings estimates for shares of Henry Schein in a report issued on Monday. Northcoast Research analyst E. Snyder now forecasts that the company will post earnings per share of $1.77 for the quarter, up from their previous forecast of $1.74. Northcoast Research has a “Buy” rating and a $218.00 price target on the stock. Northcoast Research also issued estimates for Henry Schein’s Q3 2017 earnings at $1.85 EPS, Q4 2017 earnings at $1.99 EPS, FY2017 earnings at $7.38 EPS, Q1 2018 earnings at $2.01 EPS, Q2 2018 earnings at $2.00 EPS and FY2018 earnings at $8.22 EPS.
Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, May 9th. The company reported $1.76 EPS for the quarter, beating the Zacks’ consensus estimate of $1.65 by $0.11. Henry Schein had a return on equity of 19.74% and a net margin of 4.53%. The firm had revenue of $2.92 billion for the quarter, compared to analysts’ expectations of $2.83 billion. During the same period last year, the firm earned $1.41 EPS. The company’s quarterly revenue was up 7.7% on a year-over-year basis.
Several other research analysts have also recently issued reports on the stock. Zacks Investment Research cut shares of Henry Schein from a “buy” rating to a “hold” rating in a report on Friday, June 23rd. Craig Hallum initiated coverage on shares of Henry Schein in a report on Tuesday, April 11th. They set a “hold” rating for the company. Stifel Nicolaus reissued a “hold” rating on shares of Henry Schein in a report on Thursday, July 6th. Finally, Piper Jaffray Companies initiated coverage on shares of Henry Schein in a report on Monday, June 12th. They set a “neutral” rating and a $200.00 price target for the company. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and seven have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $185.56.
Shares of Henry Schein (NASDAQ HSIC) opened at 183.79 on Tuesday. The firm has a market capitalization of $14.58 billion, a PE ratio of 27.93 and a beta of 1.09. Henry Schein has a 52-week low of $146.23 and a 52-week high of $186.99. The stock’s 50 day moving average price is $183.44 and its 200-day moving average price is $174.47.
A number of hedge funds and other institutional investors have recently modified their holdings of HSIC. BlackRock Inc. raised its position in shares of Henry Schein by 2,999.6% in the first quarter. BlackRock Inc. now owns 5,595,279 shares of the company’s stock valued at $951,028,000 after buying an additional 5,414,761 shares during the last quarter. MARSHALL WACE ASIA Ltd bought a new position in shares of Henry Schein during the first quarter valued at $50,281,000. Marshall Wace North America L.P. bought a new position in shares of Henry Schein during the first quarter valued at $50,281,000. PGGM Investments bought a new position in shares of Henry Schein during the second quarter valued at $32,623,000. Finally, JPMorgan Chase & Co. raised its position in shares of Henry Schein by 12.4% in the first quarter. JPMorgan Chase & Co. now owns 1,515,861 shares of the company’s stock valued at $257,650,000 after buying an additional 167,213 shares during the last quarter. Institutional investors own 90.87% of the company’s stock.
In other Henry Schein news, EVP Gerald A. Benjamin sold 12,578 shares of the company’s stock in a transaction dated Thursday, May 11th. The shares were sold at an average price of $175.10, for a total transaction of $2,202,407.80. Following the transaction, the executive vice president now directly owns 44,061 shares in the company, valued at $7,715,081.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.27% of the company’s stock.
About Henry Schein
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with MarketBeat.com's FREE daily email newsletter.